BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Rowan PJ. What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments? World J Virology 2015; 4(1): 13-16 [PMID: 25674513 DOI: 10.5501/wjv.v4.i1.13]
URL: https://www.wjgnet.com/2220-3249/full/v4/i1/13.htm
Number Citing Articles
1
Marta Miarons, Azhara Sánchez-Ulayar, Glòria Sempere, Sergio Marín, Josep Maria Castellví. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groupsEuropean Journal of Hospital Pharmacy 2019; 26(3): 135 doi: 10.1136/ejhpharm-2017-001352
2
Isak Sundberg, Anders Lannergård, Mia Ramklint, Janet L. Cunningham. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational studyBMC Psychiatry 2018; 18(1) doi: 10.1186/s12888-018-1735-6